Patent: 10,835,677

Summary for Patent: 10,835,677

Title:	Auto injector with cartridge retention system
Abstract:	An auto injector () for administering injection of a medicament from a cartridge () containing the medicament, the auto injector comprising: a cartridge receiver () with a cartridge receiver compartment () configured to receive a cartridge assembly () with at least one cartridge retention member () when inserted through a cartridge receiver opening () along a longitudinal axis; and an ejector () configured to support the cartridge assembly () by being suspended to move along the longitudinal direction and being spring-loaded in the direction opposite of the receiving direction. The cartridge receiver compartment () has a first section (), at a first distance from the cartridge receiver opening (), with inwardly extending first guide members () that extends over first guide member angles () and are spaced apart to form a passage () at passage angles () between the inward first guide members (); wherein the inward first guide members () form a first bore () accepting the cartridge assembly () when inserted through the cartridge receiver opening (). The cartridge receiver compartment () has a second section () with an annular shape, at a second distance from the cartridge receiver opening (), and with second guide members () with first faces () that are inclined about a radial axis to the longitudinal axis and angularly arranged to extend at least partly over the passage angles () and the first guide member angles ().
Inventor(s):	Fabricius Paul Erik, Madsen Flemming, Olesen Jan
Assignee:	Ascendis Pharma A/S
Application Number:	US16060574
Patent Claims:	see list of patent claims

United States Patent 10,835,677 Claims and Patent Landscape Analysis (US 10,835,677)

Insufficient claim text was provided to perform a complete, clause-level analysis of US 10,835,677, map each asserted claim element to prior art, and determine the practical patent-coverage footprint (composition, formulation, method-of-use, and/or manufacturing claims). Without the claim set, a correct “what’s actually protected” assessment cannot be produced, and any downstream assessment of validity risk, design-around routes, or licensing exposure would be speculative.

What information is required to analyze the claims of US 10,835,677?

A claim-by-claim landscape analysis requires, at minimum:

• the full asserted claim set (including dependent claim dependencies), or the exact “claims are:” text that you referenced
• the independent claims and their limitations (active ingredient, salt form, dosage form, regimen, parameters, catalysts, process steps, etc.)
• the patent’s title/abstract and inventors/assignees (to anchor jurisdictional and prosecution context)

Why can’t a defensible patent-coverage and validity analysis be completed?

US patent landscape work depends on claim construction inputs. Without the claim language:

• claim charts cannot be built
• prior-art anticipation/obviousness mapping cannot be performed
• “scope” (functional breadth vs structural limits) cannot be determined
• freedom-to-operate conclusions and generic/biosimilar launch risk scenarios cannot be grounded in claim elements

US 10,835,677 patent landscape: what can be concluded without claim text?

Nothing substantive on claim scope, likely validity under 102/103, enforceability posture, or design-around options can be stated with required precision.

Key Takeaways

• A comprehensive, critical analysis of US 10,835,677 requires the full claim text referenced as “The claims are:” in your prompt.
• Without the claim language, no accurate mapping to prior art, no coverage assessment, and no licensing or litigation exposure analysis can be produced.

FAQs

1. How do I identify the right claims to analyze for US patent 10,835,677?
2. What claim elements typically drive validity and infringement for US method-of-use patents?
3. How do independent vs dependent claims change the effective scope of US 10,835,677?
4. What prior art categories usually pose the highest risk to formulation/process claims in US patents?
5. How does claim construction affect Paragraph IV or biosimilar infringement positions?

References

No sources were cited because no patent claim content or bibliographic/patent-context data was provided beyond the number “US 10,835,677.”

Details for Patent 10,835,677

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ascendis Pharma Endocrinology Division A/s	SKYTROFA	lonapegsomatropin-tcgd	For Injection	761177	August 25, 2021		2036-12-29

International Patent Family for US Patent 10,835,677

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2017114906
World Intellectual Property Organization (WIPO)	2017114907
United States of America	11524115
United States of America	2018361068